Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.
about
Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patientsPopulation pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patientsCYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patientsEffect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group studyDepressogenic effects of medications: a reviewPharmacogenetics as a tool to tailor antiretroviral therapy: A reviewPerspectives on pharmacogenomics of antiretroviral medications and HIV-associated comorbiditiesEfavirenz and the CNS: what we already know and questions that need to be answeredEfavirenz plasma concentrations and cytochrome 2B6 polymorphismsInfluence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patientsTherapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapyDifferent frequencies of drug resistance mutations among HIV-1 subtypes circulating in China: a comprehensive studyPharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypesEfavirenz in the therapy of HIV infection.CYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adultsContribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and responseSecondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.Can therapeutic drug monitoring improve pharmacotherapy of HIV infection in adolescents?Pharmacokinetics of darunavir at 900 milligrams and ritonavir at 100 milligrams once daily when coadministered with efavirenz at 600 milligrams once daily in healthy volunteersNeurological and psychiatric adverse effects of antiretroviral drugs.Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort.Synergistically enhanced CYP2B6 inducibility between a polymorphic mutation in CYP2B6 promoter and pregnane X receptor activation.Effect of Host Genetic Variation on the Pharmacokinetics and Clinical Response of Non-nucleoside Reverse Transcriptase Inhibitors.CYP2B6: new insights into a historically overlooked cytochrome P450 isozymeAdherence to highly active antiretroviral therapy in a tertiary care hospital in West Bengal, India.Pharmacogenomics of antimicrobial agents.The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future.Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteersPopulation pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients.CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe.Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz.Role of the Pharmacist in Caring for Patients with HIV/AIDS: Clinical Practice Guidelines.Effects of CYP2B6 and CYP1A2 Genetic Variation on Nevirapine Plasma Concentration and Pharmacodynamics as Measured by CD4 Cell Count in Zimbabwean HIV-Infected Patients.Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment.A pharmacogenomic prospective randomized controlled trial of CYP2B6 polymorphisms and efavirenz dose adjustment among HIV-infected Thai patients: a pilot study.An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS PatientsIndividualization of antiretroviral therapy.Bioactivation of chlorpyrifos by CYP2B6 variants.Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults.
P2860
Q21245026-AA417498-8225-415E-A9EF-F3302F423642Q24602072-0DF29D7E-6E0F-4D33-B5C2-0844D37D8571Q24606937-4F6F25AF-BC4F-434A-ADF8-7CD0EA79F456Q24633579-C32D90BA-ED89-4A3A-98B6-EF4E42A4344DQ24635465-9954ADC4-AEF3-488A-8D4A-5D322F71E3F5Q26797938-EBAD2C78-5C07-4170-9702-9F5C2A218A0EQ26853274-59022CFF-4EE7-471C-8464-171F310186C1Q28085028-D77B652E-6C00-43BE-B0D3-81A1B6677D31Q28293288-B6394085-859C-443E-A1D3-0842756C1E11Q28293875-96D0718E-A538-4E9D-A087-D1F51646B1FDQ28539806-D1CE2CD1-C8AE-4DF5-94B3-B4657ABF5894Q28541365-D997629C-D053-4DA3-9E1C-336D13C3AFAFQ31150044-66868D8E-7E36-41FC-BB6D-4A459835C025Q33607011-B34C0824-2EC8-49C6-9183-EE255BF061FDQ33623024-BBC0C292-AD88-4446-81F8-3FC2D9A8D786Q33809438-80281AEC-D526-4266-BAED-D55682104F3AQ33903933-F19717BB-6109-4A85-BE2B-BA2D69EE321AQ33909996-0B0B0A93-C7A3-4C79-B049-DEFED76B9D64Q33914723-B3E38C07-43D8-43FD-A972-03AC2F3FD157Q33962854-E560512B-1BB7-494A-92E9-04E67031BED2Q34039419-9A3DE346-F192-4993-8FD6-71DF390772F1Q34060396-2B131EEC-0C36-49B8-A98F-C2D7D4D56FC9Q34310059-00B38CF7-DC32-4C0E-8E9E-0C40D96D23EDQ34443184-774DE197-D163-446B-B0C1-E5569A39A80FQ34824471-BEC1B2A0-5DC7-4517-A988-7BD4C6E5BC53Q34928552-745FA433-F95E-46E9-A125-C6B37A841A0DQ34977413-667F5349-A070-429E-A746-0176B873E64CQ35023687-27039F77-7CAA-429A-9BA7-B8322A813A90Q35065867-89BB1BCA-42A7-435D-B459-A5D144EEEB2AQ35364120-702D3BBE-2C33-429D-B73A-C1269C20940DQ35518558-1C6A4451-CE5D-47D2-9D1D-FB645AAD44F1Q35547723-19E2C75E-15F5-450E-A735-9E66B412A4ECQ35898538-290CC707-B096-4373-8714-34BD9172084DQ36074119-71D9F490-27A6-4C1A-B630-9B6DAA60DC7BQ36079108-ABFCB499-7EF5-40DB-AC5B-2F783D19019CQ36263781-3C9080C4-BA48-49AC-8655-6C200B196C51Q36437792-3F90D735-09FF-445B-BAB9-C62E668BC4F6Q36441423-46F11EFB-22E1-4953-8444-FAB00826A712Q36462008-E3E6FBF1-9C4F-4D82-A120-B98A8D9E31DBQ36468146-52FD089C-3A54-4F78-877A-DE1B7EC7D70F
P2860
Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Successful efavirenz dose redu ...... ytochrome P450 2B6 *6 and *26.
@en
Successful efavirenz dose redu ...... ytochrome P450 2B6 *6 and *26.
@nl
type
label
Successful efavirenz dose redu ...... ytochrome P450 2B6 *6 and *26.
@en
Successful efavirenz dose redu ...... ytochrome P450 2B6 *6 and *26.
@nl
prefLabel
Successful efavirenz dose redu ...... ytochrome P450 2B6 *6 and *26.
@en
Successful efavirenz dose redu ...... ytochrome P450 2B6 *6 and *26.
@nl
P2093
P2860
P356
P1476
Successful efavirenz dose redu ...... ytochrome P450 2B6 *6 and *26.
@en
P2093
Akiro Kimura
Fumitake Gejyo
Hiroki Tsukada
Hiroyuki Gatanaga
Katsuya Fujimoto
Kiyoto Tsuchiya
Masahide Horiba
Masahiro Yamamoto
Mikio Ueda
P2860
P304
P356
10.1086/522175
P407
P50
P577
2007-09-24T00:00:00Z